Dignify Therapeutics is excited to announce that Eric Green, JD, has joined Dignify Therapeutics as an Independent Manager and active member of the Board of Directors, where he will be integral to Dignify’s next round of venture fund-raising and negotiating strategic partnerships.
Mr. Green received his MBA from University of London, Cass Business School and his JD from Rutgers University. Mr. Green was General Counsel, Chief Compliance Officer, and Secretary at inVentiv Health until last year, when inVentiv was sold to INC Research in a $7B transaction in which Eric played a pivotal role. Before inVentiv, Mr. Green spent 11 years at Quintiles Transnational Corp. during which time he served as Vice-President & General Counsel of the Commercial division.
According to Dr. Karl B. Thor, CSO of Dignify, “Dignify has a very strong scientific team that has provided strong rationale to support a number of attractive programs for improving the lives of people with neurological disorders such as spinal cord injury. Now that we have this strong scientific foundation, we needed to add someone with experience and expertise on the business side of our company. Eric provides the strategic business development expertise that Dignify requires to move our projects into the clinic. He is a welcome addition to the team”. Dr. Ed Burgard, President of Dignify, added, “It was important for Dignify to find a business person who shares our passion to help resolve the many health burdens that spinal injured individuals and their caregivers must bear. Eric not only provides an executive level of business understanding but is also a person who cares deeply about our mission.”
In reply, Mr. Green stated, “I am very enthusiastic to work with the Dignify team to bring new products to the market. One of the most exciting aspects is that their programs include “first-ever” therapies that target a severe, unmet, medical need; yet they have little or no competition in their therapeutic area.”
About Dignify Therapeutics LLC
Founded by a team of serial entrepreneurs who are internationally-recognized scientists and clinicians, Dignify Therapeutics’ mission is to provide safe, effective, practical and convenient, pharmaceutical agents to treat bladder and bowel voiding dysfunctions. The Company has been funded by RA Capital Management, Eshelman Ventures, the North Carolina Biotechnology Center, NIDDK, NINDS, NICHD, NIA and the One NC Small Business Program. Dignify, a member of the Blackstone Entrepreneur Network, is located at the First Flight Venture Center in Research Triangle Park, North Carolina.